Myriad Genetics (MYGN -2.9%) shares slide after the U.S. Supreme Court agreed to hear a challenge to the practice of issuing patents on human genes. Goldman Sachs cuts shares to Neutral from Buy on concerns that a final decision likely won't be reached before midyear. But Jefferies maintains its Buy rating, believing MYGN's patents should ultimately be upheld.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Wed, 3:34PM)
at Nasdaq.com (Feb 12, 2015)
at Nasdaq.com (Jan 29, 2015)
at Nasdaq.com (Jan 22, 2015)
at Nasdaq.com (Jan 21, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs